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OBJECTIVES: Single-pill combination therapy (amlodipine/atorvastatin) might be more effective than dou-
ble-pill therapy (amlodipine+atorvastatin) in patients with diabetes and concomitant hypertension requiring 
statin therapy. We compared the cost-effectiveness of a single-pill with that of double-pill for control of low 
density lipoprotein cholesterol (LDL-C) levels, with the ultimate goal of cardiovascular disease prevention, in 
these patients using a cost-effectiveness analysis model that considered medication adherence. 
METHODS: Effectiveness was defined as the percentage (%) attainment of target LDL-C levels (<100 mg/dL) 
based on adherence for each therapy. Adherence was defined as compliance to medication (≥80% proportion 
of days covered). A systematic review of the literature was conducted to determine the proportion of patients 
who were adherent and target goal attainment based on adherence level. The annual medication costs were 
based on the adherence levels for each regimen. The average cost-effectiveness ratio (ACER) was calculated as 
the cost per % attainment of the target LDL-C level. 
RESULTS: The ACER for the single-pill regimen was lower than for the double-pill regimen (4,123 vs. 6,062 
Korean won per 1% achievement of target goal). Compared with the double-pill, the medication costs were 
approximately 32% lower with the single-pill. 
CONCLUSION: A single-pill for reductions in LDL-C is cost-effective compared with double-pill in hyperten-
sive patients with type 2 diabetes. 
KEY WORDS: Atorvastatin calcium, Amlodipine besylate, Medication adherence, Low density lipoprotein cholesterol, Cost-effec-
tiveness analysis 
INTRODUCTION
According to literature published in 2011, the prevalence of 
cardiovascular diseases (CVDs) is sharply increasing, as are the 
related mortality rates. This trend is reportedly related to the in-
creasing rates of hypertension, diabetes, dyslipidemia, and obe-
sity [1]. Furthermore, when these diseases are concomitant, the 
risk of CVDs increases. As such, proactive management of these 
risk factors is critical [2]. Particularly for patients with diabetes, 
the additional burden of hypertension and dyslipidemia signifi-
cantly increases the risk of CVDs. Therefore, recent treatment 
guidelines recommend strict control of blood cholesterol levels 
(low density lipoprotein cholesterol [LDL-C] <100 mg/dL) in 
addition to effective blood pressure management to prevent 
CVDs [3,4]. 
In general, less than half of treated patients achieve and main-
tain the target blood pressure and cholesterol levels [5], which 
might be attributed to rates of medication adherence [6]. Medi-
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cation adherence is a critically important factor influencing treat-
ment outcomes and management of many acute and chronic 
health conditions [7]. Low adherence is reportedly ascribable 
to the prescription of multiple medications and complex medi-
cation regimens. Therefore, simpler regimens of single-pill might 
have improved medication adherence and subsequently treat-
ment outcomes [8,9].
A blood pressure-lowering agent, amlodipine besylate (referr-
ed to as amlodipine), and a lipid-lowering agent, atorvastatin 
calcium (referred to as atorvastatin), which has a bio-profile equi-
valent to its parent compounds [10], combined in a single-pill 
significantly improves medication adherence rates [11]. There-
fore, it is likely that single-pill will help patients reach their tar-
get blood pressure and cholesterol levels. 
Because single-pill is generally less expensive than the dou-
ble-pill, the overall economic burden of medications could de-
crease with the use of single-pill. However, the actual economic 
effects of potentially improved medication adherence need to 
be evaluated because patients with low medication adherence 
likely spend less on medications anyway and a low adherence 
rate would negatively influence the treatment outcomes. This 
study aimed to examine and compare the cost-effectiveness of 
a single-pill regimen (amlodipine/atorvastatin) with a double-
pill regimen (amlodipine+atorvastatin) in patients with diabe-
tes and concomitant hypertension who also require cholesterol 
management. 
Cost-effectiveness analysis (CEA) is a form of economic anal-
ysis that helps identify rational methods to allocate resources for 
public health. It is designed to evaluate the relative costs and 
outcomes of specific medications while considering quality of 
life (QOL). The analysis compares the clinical usefulness with 
potential costs to identify an alternative that maximizes health 
for a given set of resource constraints. 
MATERIALS AND METHODS
The three main types of costs that are relevant in a CEA are 
direct costs (e.g., medical and non-medical costs) and indirect 
costs (e.g., productivity loss) [12]. Medical costs refer to expens-
es paid to utilize medical services (e.g., doctor and hospital vis-
its, in-patient treatments) and purchase necessary medical equip-
ment (e.g., medications). Non-medical costs include expenses 
that typically accompany medical costs, including nursing care 
fees, transportation fees, and other financial burdens placed on 
family members for patient care. Finally, productivity loss refers 
to the economic loss from treatment of illnesses or premature 
deaths resulting from illnesses. Direct medical costs are the most 
relevant in terms of an economic analysis. Cost evaluation meth-
ods used in economic analysis vary only slightly. However, de-
pending on the definition of the outcome, cost-minimization 
analysis (CMA), CEA, cost-utility analysis (CUA), or cost-bene-
fit analysis (CBA) can be used [13].
CMA is used to compare the costs when the clinical effective-
ness of alternatives has proven to be equal. With this tool, the 
optimal option is the one with the lowest associated costs. CEA 
and CUA are used to evaluate the costs as well as the outcomes 
of alternatives when the outcomes are known to vary. In partic-
ular, CUA considers both the length of life and QOL by incor-
porating indices such as quality adjusted life years and healthy 
years equivalents. CBA is a quantitative tool that calculates in-
tangible benefits of improved health and life extension in terms 
of dollar values [13]. 
This study utilized CEA to compare both the clinical effec-
tiveness and costs of the treatment alternatives. For cost estima-
tion, only the medication costs were considered based on the 
assumption that all other associated costs were equal. Addition-
ally, the medication-related outcomes were assumed equal, and 
the patient’s medication adherence was considered the only 
factor potentially affecting this balance. 
A decision analytic model is established for a comprehensive 
economic analysis that considers and integrates various data re-
lated to costs and effects. A decision tree model and Markov 
model are typically used for decision analytic models. This study 
employed the former, which calculates the expected costs and 
outcomes of each treatment alternative by integrating the data 
on potential health outcomes and costs. 
A level of uncertainty is expected to accompany economic 
analysis because they integrate multiple research findings based 
on various assumptions. However, to verify and minimize the 
uncertainties, a sensitivity analysis is performed for the variables 
used to estimate costs and effects. In this study, sensitivity anal-
ysis were performed for medication adherence rates and target 
goal attainment rates based on adherence. 
Cost-effectiveness analysis model 
The CEA model examined the following two treatment alter-
natives for patients with hypertension and diabetes: a single-pill 
regimen with amlodipine/atorvastatin (referred to as single-pill) 
and a double-pill regimen with amlodipine and atorvastatin (re-
ferred to as double-pill). For each treatment alternative, the pa-
tients were classified into an adherent or non-adherent group 
depending on adherence. Ultimately, a CEA was performed, 
which incorporated the adherence rates observed for each treat-
ment (Figure 1).
The analysis model of this study evaluated the cost-effective-
ness of the use of amlodipine and atorvastatin in patients with 
diabetes who were on blood pressure-lowering medication to 
reach the target LDL-C level. 
Effectiveness was defined as the proportion (%) of patients 
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who attained the target LDL-C level with treatment. The target 
LDL-C level was <100 mg/dL, which is the level for high-risk 
patients in the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP ATP III) guidelines [4]. The bio-equi-
valence of the two treatment alternatives has been demonstrat-
ed [10]. As such, any disparity between the effectiveness of the 
two is assumed to stem from patients’ adherence to the medi-
cations. Generally, medication adherence is described as pro-
portion of days covered (PDC) or medication possession ratio 
(MPR), with a standard of 80% [14]. Therefore, adherence was 
defined as PDC ≥80%, and non-adherence as PDC <80%. 
The average cost-effectiveness ratios (ACERs) of annual choles-
terol treatments for hypertensive patients with diabetes were 
analyzed. The treatment regimens were assumed to be once 
daily for a year, without variations in the amount or concentra-
tion. For each treatment, the ACER was calculated as the cost 
associated with 1% attainment of the treatment target. 
Data source 
Table 1 displays the literature selected for this study. To deter-
mine the medication adherence rate, a systematic online litera-
ture search was conducted with “([amlodipine AND atorvas-
tatin AND diabetes] AND adherence)” and “([amlodipine AND 
atorvastatin AND diabetes] AND compliance)” as key words. 
The search resulted in 19 and 39 relevant publications, respec-
tively. Initially, the titles and abstracts were reviewed to exclude 
Table 1. Source of data in the model from the systematic review
Author Patients Treatment Adherence definition Endpoint Extracted data
Probability of adherence
Patel et al. [11] Adults taking a CCB or statin  
(but not both) who then initiated 
treatment with SPAA or added 
CCB to statin (or vice versa)
Co-administration  
vs. single-pill  
administration
PDC ≥80% % of patients with PDC 
≥80 %
ATR/AML: 67.7%
ATR+AML: 49.9%
Chapman et al.  
[15]
Patients with co-morbid  
hypertension and dyslipidemia 
at high risk for cardiovascular 
disease
Co-administration  
vs. single-pill  
administration
PDC ≥80% % of adherent patient Diabetes adherence OR (vs. non-
coronary artery disease)
Adjusted OR (95% CI): 1.06 (0.96, 
1.17)
Unadjusted OR (95% CI): 0.99 (0.90, 
1.08) 
LDL-C level accord-
ing to adherence 
level
Parris et al. [16] Patients with diabetes and  
dyslipidemia
Statin PDC ≥80% LDL-C goal (<100 mg/
dL) attainment  
according to  
adherence level
PDC≥80% (MPR, %):  56-78 
PDC<80% (MPR. %): 16-42
CCB, calcium channel blocker; SPAA, single-pill amlodipine/atorvastatin; PDC, proportion of days covered; ATR, atorvastatin; AML, amlodipine; OR, odds ra-
tio; CI, confidence interval; LDL-C, low density lipoprotein cholesterol; MPR, medication possession ratio. 
Figure 1. Cost-effectiveness analysis model. ATR, atorvastatin; AML, amlodipine; LDL-C, low density lipoprotein cholesterol.
Diabetes with hypertention
Single-pill 
(ATR/AML)
Adherent
Adherent
Non-adherent
Non-adherent
Adherence rate of general patient×diabetes odds ratio
Attainment (target LDL-C level)
Not attainment (target LDL-C level)
Attainment (target LDL-C level)
Not attainment (target LDL-C level)
Attainment (target LDL-C level)
Not attainment (target LDL-C level)
Attainment (target LDL-C level)
Not attainment (target LDL-C level)
Adherence rate of general patient×diabetes odds ratio
1% of adherent
1% of adherent
Double-pill 
(ATR+AML)
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literature that did not meet the study purpose such as non-ran-
domized clinical trials as well as patient groups and outcomes 
that did not meet the criteria. However, accurate effectiveness 
values for medication adherence rates in patients with diabetes 
were not available; therefore, we decided to estimate the effec-
tiveness values based on research data of the medication adher-
ence rates in the general patient population and subgroups of 
patients with diabetes. This required a re-examination of the 
sear ch results, and two publications were selected: one pertain-
ing to the adherence rates and effectiveness values in the gen-
eral patient population [11] and the other presented odds ratios 
(ORs) of adherence rates in patients with diabetes [15]. 
Subsequently, another systematic online literature search was 
conducted with “diabetes AND LDL-C AND atorvastatin AND 
adherence” as key words to retrieve data pertaining to the tar-
get goal attainment based on adherence. The key words used in 
the previous literature search were used. Ultimately, one publi-
cation was selected [16] that analyzed the target LDL-C attain-
ment rates based on the adherence rates in patients with diabe-
tes and high cholesterol. The data for this study were extracted 
from the literature. 
The medication costs were obtained from data published by 
the Health Insurance Review and Assessment Services. The wei-
ghted average medication costs of September 2014 were used 
for the price of the single-pill (5 mg amlodipine/10 mg atorvas-
tatin). The 2013 annual weighted average medication costs by 
compound were used for the price of the double-pill (5 mg am-
lodipine and 10 mg atorvastatin). 
Medication adherence 
Medication adherence rates in the general patient population 
[11] as well as the ORs for patients with diabetes [15] were used 
to estimate medication adherence rates for the two treatments 
in this study.
Adherence rates of 67.7 and 49.9% were used for the single-
pill and double-pill in general patients, respectively [11]. For 
the medication adherence OR, a sensitivity analysis was per-
formed using an unadjusted OR that reflected various factors, 
including diabetes, that potentially affect adherence rates (age, 
smoking status, and CVD history). In other words, a sensitivity 
analysis was performed that did not hold the factors constant, 
other than diabetes. Calculated adherence rates used for this 
analysis were 67.0 and 49.4% for the single-pill and double-pill 
in diabetes patients, respectively. An adjusted OR of 1.06 was 
used, for which the factors other than diabetes were also held 
constant (age, smo king status, and history of CVD) in this study. 
Target goal attainment rates 
Because the bio-equivalence of the two treatments has been 
demonstrated, an equal proportion of patients with diabetes 
who attained the target LDL-C level were assumed for both of 
the treatments. According to the retrieved literature [16], the 
attainment rates were 56 to 78% and 16 to 42% for the adher-
ent and non-adherent groups, respectively. For our analysis, the 
median values (adherent group, 67%; non-adherent group, 29%) 
were used. An additional sensitivity analysis was performed 
that incorporated the minimum and maximum attainment rates 
suggested in the literature. 
Costs 
Medication costs reflecting adherence rates were assumed to 
be distributed near the top 80% of the adherence rate. In other 
words, for a patient in the adherent group, the adherence rate 
would be PDC≥80%, indicating that the patient adhered to 
the medication regimen for 292 to 365 days of the year. There-
fore, it was assumed that the patient would adhere to the regi-
men an average 350 days per year, which is at the top 80% of 
the range. For a patient in the non-adherent group, the adher-
ence rate would be <80%, indicating that the patient adhered 
to the regimen for 0 to 291 days of the year. Therefore, it was 
assumed that the patient would adhere to the regimen for an 
average of 232 days per year, which is at the top 80% of the 
range [17]. 
RESULTS
The results of the economic analysis are expressed using CER, 
which integrates costs and clinical effectiveness. CER can be di-
vided into ACER and the incremental cost-effectiveness ratio 
Table 2. Drug cost for each medication regimen
Alternative Compliance
Cost Treatment cost  
(KRW)
Average cost  
(KRW)Unit price (KRW) Treatment period (d)
Single-pill (ATR/AML) Adherent1
Non-adherent
733
733
350
232
256,550
170,056
228,612
Double-pill (ATR+AML) Adherent1
Non-adherent
1,011
1,011
350
232
353,850
234,552
294,082
KRW, Korean won; ATR, atorvastatin; AML, amlodipine.
1Adherent≥80% proportion of days covered: 2013 weighted average price used for unit price. 
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(ICER). ACER compares the ACER of one alternative with an-
other, and the smaller the ACER, the more cost effective the al-
ternative. ICER is an index used to identify the potential costs 
associated with improving the outcome by one unit; it is ob-
tained by dividing the differences in outcomes by the differenc-
es in costs. 
In this study, ACER was used. An base case analysis of the 
medication adherence and target goal attainment rates resulted 
in a 56.3% effectiveness value for the single-pill and 49.1% for 
the double-pill. The sensitivity analysis incorporating the mini-
mum and maximum target goal attainment rates resulted in 
44.7% for the single-pill and 37.2% for the double-pill with 
the minimum value and 67.8 and 61.0%, respectively, with the 
maximum value. The sensitivity analysis for the adherence rates 
effectiveness values (using an unadjusted OR based on the same 
target attainment rates) resulted in 54.5 and 47.8% for the sin-
gle-pill and double-pill, respectively. 
The assumption of medication costs around the top 80% range 
resulted in estimated medication costs of 256,550 Korean won 
(KRW) for the single-pill and 353,850 KRW for the double-pill. 
The base case analysis, which took into account the medication 
adherence rates, resulted in medication costs of 228,612 KRW 
for the single-pill and 294,082 KRW for the double-pill. A sen-
sitivity analysis resulted in medication costs of 228,027 KRW 
for the single-pill and 293,486 KRW for the double-pill (Table 2). 
Cost-effectiveness
The results of an base case analysis indicated that a 1% im-
provement in the attainment rates incurred an additional 4,123 
KRW for the single-pill and 6,062 KRW for the double-pill. This 
translates into an approximate 32% savings with the single-pill 
for the same level of outcome, indicating that the single-pill is a 
more efficient alternative than the double-pill (Table 3).
The sensitivity analysis regarding changes in target goal attain-
ment rates revealed that, in both treatments, ACER decreased 
as the attainment rates increased, from 67 to 78%, with the 
same adherence rate used in the base case analysis: single-pill, 
from 4,123 to 3,424 KRW; double-pill, from 6,062 to 4,880 
KRW) (Figure 2A). Regarding the single-pill and double-pill, 
the ACER of the single-pill was lower than that of the double-
pill (3,424 vs. 4,880 KRW), indicating that the single-pill regi-
men is more efficient.
Table 3. Average cost-effectiveness ratios 
Compliance rate (%) Target goal attainment  (LDL-C level <100 mg/dL, %)
Probability  
(%)
Total cost 
(KRW)
ACER  
(KRW)
Single-pill (ATR/AML) Adherence (71.8) Attainment (67.0) 56.3 232,126 4,123
Not attainment (33.0)
Non-adherence (28.2) Attainment (29.0)
Not attainment (71.0)
Double-pill (ATR+AML) Adherence (52.9) Attainment (67.0) 49.1 297,653 6,062
Not attainment (33.0)
Non-adherence (47.1) Attainment (29.0)
Not attainment (71.0)
Modified from Patel BV, et al. Vasc Health Risk Manag 2008:4:673-681 [11].
LDL-C, low density lipoprotein cholesterol; KRW, Korean won; ATR, atorvastatin; AML, amlodipine.
Figure 2. ACER based on adjusted odds ratios (A) and unadjusted odds ratios (B) in sensitivity analysis. ACER, average cost-effectiveness 
ratio; KRW, Korean won.
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According to the sensitivity analysis using the unadjusted OR 
to calculate the medication adherence rates, the ACERs were 
higher than those in the base case analysis (single-pill, from 
4,123 to 4,184 KRW; double-pill, from 6,062 to 6,140 KRW). 
Nevertheless, a similar pattern is preserved here, in which the 
single-pill shows lower ACERs than the double-pill (minimum, 
5,328<8,198 KRW; median, 4,184<6,140 KRW; maximum, 
3,450<4,908 KRW) (Figure 2B), indicating that the single-pill 
is the more efficient alternative.
In other words, all of the ACER findings indicate that the sin-
gle-pill is more efficient in meeting the target goal than the dou-
ble-pill.
DISCUSSION
Improved standards of living and increasing interest in a heal-
thy lifestyle are increasing the cost of healthcare. Incorporating 
medication costs into the existing effect, efficacy, and safety stan-
dards is critically important to ensure effective healthcare spend-
ing. Because a single combination pill costs less than separate 
pills for the same medications in the domestic marketplace, it 
could be assumed that the total medication cost of a single-pill 
would be lower than that of a double-pill. However, the transfer 
of potential savings into economic gains needs to consider med-
ication adherence rates.
Medication adherence rates are expressed as PDC or MPR; 
both are calculated using the number of medications prescribed 
during the prescription period. However, MPR is expressed as a 
ratio of the prescription period and number of medications, whe-
reas PDC is expressed as a percentage of the number of medi-
cations during the prescription period. PDC is thought to be 
more consistent than MPR, which is a relative figure [14,18]. 
Therefore, most research uses PDC to express medication ad-
herence rates. An 80% cut-off point defines high and low ad-
herence rates. 
Assuming adherence to the medication by all patients, similar 
effectiveness and lower medication cost with a single-pill can 
be predicted easily without the need of a CEA. In reality, medi-
cation adherence rates vary depending on the patient charac-
teristics and specific diseases. Therefore, a CEA that considers 
these differences are needed, which is a major limitation of this 
study. 
This study aimed to determine, through a CEA model that 
considered adherence rates, a potential improvement in medi-
cation adherence rates and economic benefits of single-pill and 
double-pill prescribed to control the cholesterol levels of patients 
with diabetes and controlled hypertension. 
The results indicated that, with each 1% improvement in the 
attainment rates, 4,123 KRW was required for the single-pill 
and 6,062 KRW for the double-pill, indicating that the single-
pill is 32% less costly than the double-pill for the same outcome 
level. Also, for the sensitivity analysis of adherence and target 
goal attainment according to adherence, ACER decreases as the 
target goal attainment increase.
In 2013, cerebrovascular diseases, CVDs, and diabetes acco-
unted for the second, third, and fifth causes of deaths in Korea, 
respectively [19]. Diabetes, in particular, is known to increase 
the mortality rates of CVDs by 2.5 to 4 times [20]. In patients 
with diabetes, hypertension is closely associated with CVDs, 
and approximately 80% of patients with diabetes have concom-
itant hypertension [21]. Hypertension accelerates the progres-
sion and increases the incidence of CVDs. According to the cur-
rent diagnostic criteria, approximately 50 to 80% of patients 
with diabetes also have high cholesterol. Because high choles-
terol is a risk factor for CVDs, proactive treatment is particular-
ly important. 
Most international examination guidelines recommend the 
evaluation of the overall cholesterol profile (total cholesterol, 
high density lipoprotein cholesterol, and LDL-C) [22-24]. Re-
cently published Korean guidelines for hypertension manage-
ment indicate that patients with diabetes are at a higher risk for 
CVDs and recommend that blood pressure should be maintained 
at <140/85 mmHg [25]. Other research also indicates that indi-
viduals with risk factors, such as diabetes and hypertension, should 
maintain LDL-C levels below the threshold to effectively pre-
vent CVDs [26,27]. 
The NCEP ATP III, the US diagnostic guidelines for hyperlip-
idemia, use ranges of risk levels for the major CVD risk factors 
to base treatment recommendations for each risk level. Accord-
ing to these guidelines, diabetes considered a risk factor for cor-
onary heart disease, and the LDL-C level should be maintained 
at 100 mg/dL. 
According to a recently published Korean study of diabetes, 
62.6% of patients with diabetes have LDL-C levels <100 mg/
dL [28]. This low rate of cholesterol control underscores the im-
portance of evaluating the effects of a single combination pill, 
as it may contribute to improved medication adherence rates. 
Korean studies that have compared the cost-effectiveness of a 
single-pill with that of a double-pill based on adherence rates 
are rare.  A 2014 study compared the economic analysis, through 
improved medication compliance, of a single-pill combination 
therapy with a double-pill administration for the primary pre-
vention of cardiovascular disorders in Korean patients with hy-
pertension, hyperlipidemia, and at least 3 risk factors for CVDs 
[17]. The per-individual cost of CVD prevention was used to 
determine the cost-effectiveness. The results indicated that the 
single-pill prevented 0.4 to 4.5 CVDs per 1,000 individuals by 
improving the adherence rates. The final results also showed 
that the single-pill can result in 32% cost savings. This research 
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is sorely needed because this CEA study, which evaluated the 
economic effects of the single-pill in patients with diabetes, con-
trolled hypertension, and hyperlipidemia, is thought to help guide 
the selection of medications. 
Patient with diabetes and controlled hypertension are at a great-
er risk for cerebrovascular diseases such as stroke, congestive 
heart failure, and peripheral vascular diseases. Therefore, proac-
tive treatment and prevention are needed to control and main-
tain optimal blood pressure. Diabetes accompanied by dyslipid-
emia and hypertension increases the risk of CVDs even further; 
therefore, blood pressure-lowering and cholesterol-lowering 
agents should be administered to these patients. The single-pill, 
which integrated the two agents, might help to improve medi-
cation adherence rates. 
Adherence rates generally decrease with an increasing num-
ber of medications. Therefore, a decrease in the number of med-
ications is expected to improve adherence rates. The proportion 
of patients who successfully adhere to medication regimens dou-
bles when they were on single-pill [29]. Lower adherence rates 
affect treatment outcomes, as evidenced by the superior treat-
ment outcomes observed in the adherent group compared with 
the non-adherent group. The CEA also confirmed that the sin-
gle-pill is a more efficient alternative than the double-pill. 
This study has certain limitations, requiring cautious interpre-
tation of the results. First, the probability of adherence and tar-
get LDL-C attainment rate were extracted from two different 
sources, which may have affected the accuracy of the estima-
tions. Nevertheless, uncertainties were minimized by selecting 
data after a thorough review of applicable data through a sys-
tematic research. Second, all of the effect data were from re-
search performed abroad with foreign patients. Therefore, future 
research on medication adherence and attainment rates that re-
flect the treatment situation in Korea is needed. Third, only the 
medication costs were incorporated into the CEA; therefore, the 
ability to interpret a total cost required to improve the attain-
ment rates by 1% is limited. Fourth, because patients with dia-
betes and controlled hypertension who required dyslipidemia 
management were included, the attainment rates for target blood 
pressure and LDL-C levels might not be accurate. The number 
of patients with diabetes who have successful blood pressure ma-
nagement (40%) is lower than patients without diabetes (68%), 
according to the 2011 Korea National Health and Nutrition Ex-
amination Survey [30]. Future studies are needed to determine 
the target blood pressure and cholesterol attainment rates based 
on adherence rates. Fifth, because the outcome was defined as 
target LDL-C level attainment rates, rather than prevention of 
CVD; it is difficult to identify the degree to which the addition-
al cholesterol management (in patients with diabetes and con-
trolled hypertension) contributes to CVD prevention. Never-
theless, the Heart Protection Study reported that lower LDL-C 
levels have a positive effect on primary prevention of CVD in 
patients with diabetes [31]. Additionally, the Coronary Artery 
Diabetes Study reported that the daily administration of atorv-
astatin to reduce LDL-C levels in patients with diabetes reduced 
CVD incidence, including strokes [26]. Therefore, the LDL-C 
level is associated with CVDs. Future studies that examine the 
degree to which reduced LDL-C levels can lower the risk of CVDs, 
as well as the economic analysis, are needed. 
Despite these limitations, the CEA of the treatment alterna-
tives in clinical settings in this study demonstrated that a single- 
pill is more efficient than treatment with double-pill for patients 
with diabetes and controlled hypertension who also require dys-
lipidemia management. The results of this study could help to 
select the optimal medication regimen for these patients.
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